Literature DB >> 17874133

Efficacy of nitazoxanide against experimental cryptosporidiosis in goat neonates.

Henri Viel1, Hélène Rocques, Jennifer Martin, Christophe Chartier.   

Abstract

Preliminary results obtained in mice, rats and piglets experimentally infected with Cryptosporidium sp have indicated a partial prophylactic or curative efficacy of nitazoxanide when administered between 50 and 250 mg/kg BW. In this study, the efficacy of nitazoxanide was evaluated in goat neonates experimentally infected with Cryptosporidium sp oocysts. Forty-seven 2- to 4-day-old kids were experimentally infected once on day 0 with 10(6) Cryptosporidium oocysts isolated from a dead kid, and allocated to three groups. Group 1 acted as control untreated group, group 2 received nitazoxanide for 8 days from day -1 to day 6 at a daily dose rate of 200 mg/kg BW, group 3 received nitazoxanide for 7 days from day 2 to day 8 at 100 mg/kg BW. Individual oocyst shedding was monitored by daily examination of faecal smears stained by carbol fuchsin and scored semi-quantitatively (zero to four). The other criteria included for nitazoxanide evaluation were weight gain and mortality. In the control group, oocyst shedding that started 3 days post-inoculation (PI) was maximal 6-7 days PI (mean scores ranging from 1.69 to 1.94) and became undetectable from day 16 PI. In group 2, oocyst shedding started 1 day later, peaked 9-11 days PI (1.33 to 1.5) and vanished day 18 PI. In group 3, results were similar to those of group 1 except for the mean scores ranging from 1.0 to 1.58. No significant difference was seen for weight gains between groups. Five kids died in group 1 as well as in group 3, whereas seven kids died in group 2. An acute toxicity of nitazoxanide was suspected as soon as the first 2 days of treatment.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17874133     DOI: 10.1007/s00436-007-0744-z

Source DB:  PubMed          Journal:  Parasitol Res        ISSN: 0932-0113            Impact factor:   2.289


  16 in total

1.  Evaluation of beta-cyclodextrin against natural infections of cryptosporidiosis in calves.

Authors:  J A Castro-Hermida; Y González-Losada; F Freire-Santos; M Mezo-Menéndez; E Ares-Mazás
Journal:  Vet Parasitol       Date:  2001-11-05       Impact factor: 2.738

2.  Efficacy of nitazoxanide and paromomycin in biliary tract cryptosporidiosis in an immunosuppressed gerbil model.

Authors:  A Baishanbo; G Gargala; C Duclos; A François; J-F Rossignol; J J Ballet; L Favennec
Journal:  J Antimicrob Chemother       Date:  2005-12-16       Impact factor: 5.790

3.  [A simple technic for the demonstration of cryptosporidia in feces].

Authors:  J Heine
Journal:  Zentralbl Veterinarmed B       Date:  1982-05

4.  Floppy kid syndrome caused by D-lactic acidosis in goat kids.

Authors:  Ulrich Bleul; Silvia Schwantag; Hans Stocker; Louis Corboz; Felix Grimm; Monika Engels; Nicole Borel; Hans Lutz; Marietta Schönmann; Wolfgang Kähn
Journal:  J Vet Intern Med       Date:  2006 Jul-Aug       Impact factor: 3.333

5.  Long-lasting anticryptosporidial activity of nitazoxanide in an immunosuppressed rat model.

Authors:  Xunde Li; Philippe Brasseur; Patrice Agnamey; Denis Leméteil; Loïc Favennec; Jean-Jacques Ballet; Jean-François Rossignol
Journal:  Folia Parasitol (Praha)       Date:  2003-03       Impact factor: 2.122

6.  Comparative efficacy evaluation of dicationic carbazole compounds, nitazoxanide, and paromomycin against Cryptosporidium parvum infections in a neonatal mouse model.

Authors:  B L Blagburn; K L Drain; T M Land; R G Kinard; P H Moore; D S Lindsay; D A Patrick; D W Boykin; R R Tidwell
Journal:  Antimicrob Agents Chemother       Date:  1998-11       Impact factor: 5.191

7.  Efficacy of nitazoxanide against Cryptosporidium parvum in cell culture and in animal models.

Authors:  C M Theodos; J K Griffiths; J D'Onfro; A Fairfield; S Tzipori
Journal:  Antimicrob Agents Chemother       Date:  1998-08       Impact factor: 5.191

8.  Effect of ultraviolet disinfection of drinking water on the viability of Cryptosporidium parvum oocysts.

Authors:  M J Lorenzo-Lorenzo; M E Ares-Mazas; I Villacorta-Martinez de Maturana; D Duran-Oreiro
Journal:  J Parasitol       Date:  1993-02       Impact factor: 1.276

9.  Use of nitazoxanide for gastrointestinal tract infections: treatment of protozoan parasitic infection and beyond.

Authors:  David A Bobak
Journal:  Curr Infect Dis Rep       Date:  2006-03       Impact factor: 3.725

Review 10.  A review of the importance of cryptosporidiosis in farm animals.

Authors:  D C de Graaf; E Vanopdenbosch; L M Ortega-Mora; H Abbassi; J E Peeters
Journal:  Int J Parasitol       Date:  1999-08       Impact factor: 3.981

View more
  6 in total

1.  Effects of the Chinese medicine matrine on experimental C. parvum infection in BALB/c mice and MDBK cells.

Authors:  Fu Chen; Kehe Huang
Journal:  Parasitol Res       Date:  2012-07-11       Impact factor: 2.289

2.  Efficacy of nitazoxanide to treat natural Giardia infections in dogs.

Authors:  Mario Moron-Soto; Lilia Gutierrez; Héctor Sumano; Graciela Tapia; Yazmin Alcala-Canto
Journal:  Parasit Vectors       Date:  2017-01-31       Impact factor: 3.876

Review 3.  Cryptosporidiosis: A zoonotic disease concern.

Authors:  Natapol Pumipuntu; Supawadee Piratae
Journal:  Vet World       Date:  2018-05-23

4.  The therapeutic efficacy of azithromycin and nitazoxanide in the acute pig model of Cryptosporidium hominis.

Authors:  Sangun Lee; Melanie Harwood; Don Girouard; Marvin J Meyers; Mary A Campbell; Gillian Beamer; Saul Tzipori
Journal:  PLoS One       Date:  2017-10-03       Impact factor: 3.240

5.  Cryptosporidiosis in small ruminants.

Authors:  C Paraud; C Chartier
Journal:  Small Rumin Res       Date:  2011-11-16       Impact factor: 1.611

6.  Cryptosporidium parvum Infection Depletes Butyrate Producer Bacteria in Goat Kid Microbiome.

Authors:  Mohamed Mammeri; Dasiel Alvarez Obregón; Aurélie Chevillot; Bruno Polack; Christine Julien; Thomas Pollet; Alejandro Cabezas-Cruz; Karim Tarik Adjou
Journal:  Front Microbiol       Date:  2020-10-16       Impact factor: 5.640

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.